| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/31/2013 | US20130030024 Method of Administering Pirfenidone Therapy |
| 01/31/2013 | US20130030023 Orally bioavailable dabigatran prodrugs for the treatment of diseases |
| 01/31/2013 | US20130030014 N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS |
| 01/31/2013 | US20130030011 Compounds for the reduction of beta-amyloid production |
| 01/31/2013 | US20130030008 Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
| 01/31/2013 | US20130030000 Pharmaceutical compositions for the treatment of pain and other indications |
| 01/31/2013 | US20130029999 Myosin light chain kinase inhibitor compounds, compositions and related methods of use |
| 01/31/2013 | US20130029994 N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors |
| 01/31/2013 | US20130029993 Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| 01/31/2013 | US20130029990 Pyrazole p38 map kinase inhibitors |
| 01/31/2013 | US20130029986 3-(indolyl)- or 3-(azaindolyl)- 4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarzinoma |
| 01/31/2013 | US20130029985 Novel Compounds |
| 01/31/2013 | US20130029984 Heterocyclic compounds and uses thereof |
| 01/31/2013 | US20130029982 Heterocyclic compounds and uses thereof |
| 01/31/2013 | US20130029974 6,7-dihydroimidazo[1,5-a]pyrazin-8(5h)-one derivatives as protein kinase modulators |
| 01/31/2013 | US20130029972 Notch pathway signaling inhibitor compound |
| 01/31/2013 | US20130029969 Heterocyclic compound |
| 01/31/2013 | US20130029967 Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors |
| 01/31/2013 | US20130029963 1,2,4-triazine-4-amine derivatives |
| 01/31/2013 | US20130029959 Compositions and methods for the treatment of cancer |
| 01/31/2013 | US20130029953 Progesterone antagonists |
| 01/31/2013 | US20130029950 Methods and compositions for the treatment of proliferative vascular disorders |
| 01/31/2013 | US20130029949 Substituted Quinolines and Their Use As Medicaments |
| 01/31/2013 | US20130029948 Heterocyclic autotaxin inhibitors and uses thereof |
| 01/31/2013 | US20130029944 Inhibitors of protein kinases |
| 01/31/2013 | US20130029942 Compounds and therapeutical uses thereof |
| 01/31/2013 | US20130029939 Novel glucokinase activators and methods of using same |
| 01/31/2013 | US20130029936 Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same |
| 01/31/2013 | US20130029931 Pleurotus tuber-regium polysaccharide functionalized nano-selenium hydrosol with anti-tumor activity and preparation method thereof |
| 01/31/2013 | US20130029928 Compositions comprising perfluorooctanoic acid |
| 01/31/2013 | US20130029927 Combination of lbh589 with other therapeutic agents for treating cancer |
| 01/31/2013 | US20130029926 Compositions and methods for determing cancer susceptibility |
| 01/31/2013 | US20130029925 Method for Preventing Cancer Metastasis |
| 01/31/2013 | US20130029922 Formulations from natural products, turmeric, paclitaxel, and aspirin |
| 01/31/2013 | US20130029918 Methods for reducing vein irritation |
| 01/31/2013 | US20130029910 METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST |
| 01/31/2013 | US20130029909 Treatment of cancer |
| 01/31/2013 | US20130029903 Azuvirin Peptides |
| 01/31/2013 | US20130029902 Cxc chemokine receptor 4 (cxcr4) antagonistic polypeptide |
| 01/31/2013 | US20130029901 Methods and compounds for the targeted delivery of agents to bone for interaction therewith |
| 01/31/2013 | US20130028997 Compositions, Products, Therapeutic Uses and Procedures for the Production and/or Crystallization of Extracts of Encelia Canescens LAM (Coronilla De Fraile) |
| 01/31/2013 | US20130028993 Composition and Manufacturing Processes of a Toxicity Free Botanical Drug for Curative Treatment of Chronic Diseases |
| 01/31/2013 | US20130028989 Materials and method for inhibiting replication protein a and uses thereof |
| 01/31/2013 | US20130028973 Particulate comprising a calcium-containing compound and a sugar alcohol |
| 01/31/2013 | US20130028968 Compositions and methods to relieve chronic diseases symptoms |
| 01/31/2013 | US20130028962 Triggered Cargo Release from Nanoparticle Stabilized Liposomes |
| 01/31/2013 | US20130028957 Pharmaceutical composition for treating cancer |
| 01/31/2013 | US20130028955 Sustained release oral matrix and methods of making thereof |
| 01/31/2013 | US20130028944 Novel methods for targeting cancer stem cells |
| 01/31/2013 | US20130028943 Melatonin tablet and methods of preparation and use |
| 01/31/2013 | US20130028941 Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
| 01/31/2013 | US20130028938 Solid pharmaceutical dosage form |
| 01/31/2013 | US20130028932 Compositions comprising polyglutamic acid nanoparticles and polypeptides such as cd40 agonists |
| 01/31/2013 | US20130028929 Functional beverage composition comprising chlorella and deep sea water |
| 01/31/2013 | US20130028923 Kdr peptides and vaccines comprising the same |
| 01/31/2013 | US20130028919 Targeted pyrrolobenzodiazapine conjugates |
| 01/31/2013 | US20130028917 Pyrrolobenzodiazepines and conjugates thereof |
| 01/31/2013 | US20130028915 Dendritic cell (dc)-vaccine therapy for pancreatic cancer |
| 01/31/2013 | US20130028909 Depletion of Teratoma-Forming Pluripotent Stem Cells |
| 01/31/2013 | US20130028906 Human antibodies that bind mesothelin, and uses thereof |
| 01/31/2013 | US20130028905 Human antibodies that bind mesothelin, and uses thereof |
| 01/31/2013 | US20130028904 Human antibodies that bind mesothelin, and uses thereof |
| 01/31/2013 | US20130028900 Methods and compositions for the generation and use of conformation-specific antibodies |
| 01/31/2013 | US20130028899 Treatment of cancer by inhibiting activity or expression of late sv-40 factor |
| 01/31/2013 | US20130028898 Combination therapy with cd4 lymphocyte depletion and mtor inhibitors |
| 01/31/2013 | US20130028896 Semaphorin 3C (Sema3C) Inhibitor Therapeutics, Methods, and Uses |
| 01/31/2013 | US20130028895 Exosome inhibiting agents and uses thereof |
| 01/31/2013 | US20130028891 Unconjugated Anti-TfR Antibodies and Compositions Thereof for the Treatment of Cancer |
| 01/31/2013 | US20130028890 Method for detecting regulatory t cells using expression of folate receptor 4 as indicator, method for treating diseases using the detection method, pharmaceutical composition for immunostimulation, and method for treating diseases using the composition |
| 01/31/2013 | US20130028888 Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 01/31/2013 | US20130028887 Phenylacetic acid compound |
| 01/31/2013 | US20130028886 Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and tumor initiating cells |
| 01/31/2013 | US20130028885 Methods to predict and prevent resistance to taxoid compounds |
| 01/31/2013 | US20130028877 LACTOBACILLUS JOHNSONII La1 NCC533 (CNCM I-1225) AND IMMUNE DISORDERS |
| 01/31/2013 | US20130028875 Immune Effector Cells Pre-Infected with Oncolytic Virus |
| 01/31/2013 | US20130028868 Clinical applications of a recombinant human endostatin adenovirus (e10a) injection |
| 01/31/2013 | US20130028867 Long-acting interferon beta formulation using immunoglobulin fragment |
| 01/31/2013 | US20130028862 Treatment with anti-vegf antibodies |
| 01/31/2013 | US20130028856 Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
| 01/31/2013 | US20130028849 Agent For Stimulating The Expression of Loxl |
| 01/31/2013 | US20130028843 Kallikrein 7 modulators |
| 01/31/2013 | US20130028836 Chlorotoxin polypeptides and conjugates and uses thereof |
| 01/31/2013 | US20130028835 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses |
| 01/31/2013 | CA2843359A1 Monoamine oxidase inhibitors and methods for treatment and diagnosis of prostate cancer |
| 01/31/2013 | CA2843251A1 N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors |
| 01/31/2013 | CA2843200A1 Dendritic cell (dc)-vaccine therapy for pancreatic cancer |
| 01/31/2013 | CA2843195A1 Heterocyclyl pyrimidine analogues as jak inhibitors |
| 01/31/2013 | CA2843109A1 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| 01/31/2013 | CA2842860A1 Sur-binding proteins |
| 01/31/2013 | CA2842841A1 Spirocyclic molecules as protein kinase inhibitors |
| 01/31/2013 | CA2842838A1 9-aminomethyl substituted tetracycline compounds |
| 01/31/2013 | CA2842796A1 Tumor selective chemokine modulation |
| 01/31/2013 | CA2842730A1 Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof |
| 01/31/2013 | CA2842580A1 Technique for cleaving out part of poly(a) chain and/or 3'-terminal sequence of mrna to inhibit translation reaction |
| 01/31/2013 | CA2842443A1 Synthetic lethality and the treatment of cancer |
| 01/31/2013 | CA2842053A1 Il-12 immunoconjugate |
| 01/31/2013 | CA2841178A1 Notch pathway signaling inhibitor compound |
| 01/31/2013 | CA2840029A1 Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit) |
| 01/30/2013 | EP2551347A1 Pharmaceutical composition for preventing or treating cancer |
| 01/30/2013 | EP2551282A2 Antibodies against CD38 for treatment of multiple myeloma |